The current treatment approach for hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients is focused on selecting patients who can be spared chemotherapy [1–4]. This evidence concerns the gene NR4A1 and breast carcinoma.